ClinicalTrials.gg
Not yet recruitingNCT06530186Updated Jul 31, 2024

Evaluation of a Postcoital Sponge on Self-Reported Vaginal Health Parameters

An interventional study of LiviWell Postcoital Vaginal Insert in Vaginal Infection, Vaginal Discharge and Vaginosis, sponsored by Atlantic Health System. Not yet recruiting at 1 site in United States. Open to female participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-07-31.

Sponsored by Atlantic Health System · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2024, 1 year 10 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
1,000
Allocation
Non-randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 38 studies in Vaginitis with a site in United States — 4 open to participants now, 4 under way, none of them phase 3. Vaginitis · United States.

Planned enrollment
2nd of 33
1,000 · median 77
Started
2024
with 3 others
No phase
11 of 38
2 open now
Registered
36th of 38
by date
Lead sponsor
2 of 38
Atlantic Health System

Among the 38 studies in Vaginitis with a site in United States, this one is the 2nd largest by planned enrollment of the 33 interventional ones that give a count, is one of 4 that started in 2024, is one of 11 with no phase, and was the 36th registered.

Vaginitis

98 studies on the registry are indexed under Vaginitis; 12 are open to participants now.

Browse Vaginitis studies →

Open to participants now

4 of the 38 studies in Vaginitis with a site in United States are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 5 Vaginitis studies recruiting now, 2 set no upper age limit and 3 stop at 75 or younger; none take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 38 studies in Vaginitis with a site in United States, or all of them as a file.
02

Study summary

LiviWell has developed a product designed for postcoital semen absorption. Previous studies have demonstrated the product rapidly absorbs semen, and leads to less symptoms of postcoital vaginal microbiome disruption such as vaginal odor and discharge. This study will investigate the study device, Livi, in a broader clinical setting.

Read the detailed description

LiviWell's consumer hygiene device is a post-coital vaginal insert called "Livi". Livi is comprised of an applicator, with a medical-grade polyurethane foam and retrieval string. It is designed to be inserted into the vagina after intercourse to absorb semen deposited into the vaginal canal. The result is a decrease in discharge/dripping and vaginal odor. The investigators also believe the device will lower vaginal pH, as the typical premenopausal vaginal pH is acidic (pH \~4), and semen has an alkaline pH (\~8). The resulting pH imbalance in sexually-active women not using male condoms had been shown to lead to vaginal odor, dripping, discomfort. Furthermore, the risk of bacterial vaginosis (BV) is higher in women who are sexually active and not using male condoms. The investigators have additional studies planned to evaluate if the product lowers the risk of BV.

The current study will be used to validate user needs requirements for the study device, understand pH changes after insertion, and evaluate change in symptoms of vaginal odor, discharge/dripping, and discomfort, common symptoms of vaginal microbiome disruption and bacterial vaginosis.

03

Conditions studied

  • Vaginal Infection
  • Vaginal Discharge
  • Vaginosis
  • Sexual Dysfunction

Keywords

  • vaginal odor
  • vaginal discharge
  • postcoital dripping
  • vaginal microbiome
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Over 18 (for pH subset, 18-45)
  • Sexually-active with biological men
  • Willing and able to use product
  • Resides in continental USA
  • Understands, reads, writes, and speaks English

Exclusion criteria

Exclusion Criteria:

  • Currently Pregnant or are trying to conceive
  • Unable to use device due to poor motor function
  • Unable to sign
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
1,000 participants (estimated)

Study arms

  • Experimental
    pH subset

    This subset of patients (n=100) will be checking their vaginal pH at various time intervals (before, 2-6 hours after, and 10-14 hours after sex).

    Device: LiviWell Postcoital Vaginal Insert

  • Experimental
    Main Cohort

    This subset of patients (n=900) will be providing user feedback on the study device, and will not be checking their vaginal pH

    Device: LiviWell Postcoital Vaginal Insert

Interventions

  • DeviceLiviWell Postcoital Vaginal Insert

    subjects will use Livi within minutes of completion of sex, and will remove study device in under an hour.

    Also known as: Livi

06

What researchers measure

Primary outcomes

  1. User Experience Questionnaire

    Validation of User Needs Requirements as well as patient experience

    Time frame: 24 hours

Secondary outcomes

  1. change in vaginal pH

    change in vaginal pH before and after using Livi, and before and after NOT using Livi

    Time frame: 2-6 hours, and 10-14 hours after use

07

Study locations

1 site
  • Garden State Urology
    Mountain Lakes, New Jersey 07046, United States
    • Cathy Smith, MA · Contactcsmith@gsunj.com · 973-537-5557
    • Michael Ingber, MD · Principal investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Aug 2024; primary completion for Dec 2024, 4 months later.

Of 22 interventional studies with no phase under Vaginitis, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 35. This study's planned 4 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 27, 2024
First posted
Jul 31, 2024
StartEst.
Aug 1, 2024
Primary completionEst.
Dec 31, 2024
CompletionEst.
Jan 31, 2025
Last update
Jul 31, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 31, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06530186
Lead sponsor
Atlantic Health System
Responsible party
Michael Ingber (Attending Physician, Atlantic Health System) — Principal investigator
First posted
Jul 31, 2024
Start date
Aug 1, 2024 (estimated)
Primary completion
Dec 31, 2024 (estimated)
Completion
Jan 31, 2025 (estimated)
Last update
Jul 31, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion